TC
DGX icon

Trilogy Capital’s Quest Diagnostics DGX Stock Holding History

Trilogy Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,676
Closed -$231K – 302
2023
Q4 		$231K Sell
1,676
-409
-20% -$53.8K 0.01% 244
2023
Q3 		$254K Sell
2,085
-225
-10% -$30K 0.02% 224
2023
Q2 		$334K Buy
2,310
+63
+3% +$8.69K 0.02% 213
2023
Q1 		$318K Buy
2,247
+410
+22% +$58.7K 0.02% 203
2022
Q4 		$287K Buy
+1,837
New +$264K 0.02% 209
2019
Q2 		– Sell
-2,265
Closed -$204K – 118
2019
Q1 		$204K Sell
2,265
-626
-22% -$54.2K 0.02% 118
2018
Q4 		$241K Sell
2,891
-547
-16% -$51.3K 0.03% 115
2018
Q3 		$371K Sell
3,438
-573
-14% -$62.8K 0.05% 105
2018
Q2 		$441K Sell
4,011
-586
-13% -$61K 0.06% 82
2018
Q1 		$461K Buy
+4,597
New +$471K 0.07% 80

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Trilogy Capital's DGX Position: Q1 2024 in Review

Trilogy Capital sold out of Quest Diagnostics (DGX) in Q1 2024, closing a stake of 1,676 shares — an estimated $231K sold.

Trilogy Capital first reported a position in DGX in Q1 2018 and held it in 10 quarters. The position peaked at $461K in Q1 2018. 819 funds tracked by Wall St. Rank hold DGX as of Q1 2024.

  • Trilogy Capital reported no remaining Quest Diagnostics position as of Q1 2024 after selling out during the quarter.
  • Trilogy Capital sold 1,676 Quest Diagnostics shares in Q1 2024, an estimated $231K.
  • Trilogy Capital first reported a position in Quest Diagnostics in Q1 2018 and held it in 10 quarters.
  • Trilogy Capital's Quest Diagnostics position peaked at $461K in Q1 2018.
  • 819 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2024.

Based on Trilogy Capital's 13F filing for Q1 2024, filed 17 Apr 2024.